PF-543 Citrate is a potent, selective, reversible, and sphingosine-competitive inhibitor of Sphingosine Kinase 1 (SPHK1), with an IC50 of 2 nM and a Ki of 3.6 nM; it exhibits over 100-fold selectivity for SPHK1 over SPHK2. It effectively inhibits sphingosine-1-phosphate (S1P) formation in whole blood (IC50 = 26.7 nM) and in 1483 cells (IC50 = 1.0 nM for C17-S1P). PF-543 Citrate induces apoptosis, necrosis, and autophagy, and causes dose-dependent depletion of intracellular S1P (EC50 = 8.4 nM) with a concomitant increase in sphingosine levels. In vitro, it abolishes SPHK1 expression at nanomolar concentrations and activates caspase-3/7 in human pulmonary arterial smooth muscle (PASM) cells. In vivo, it reduces right ventricular hypertrophy in a mouse model of hypoxia-induced pulmonary arterial hypertension, associated with decreased p53 expression and increased Nrf2 antioxidant pathway activation.